Cantor Fitzgerald Reiterates Overweight on Axsome Therapeutics, Maintains $108 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Axsome Therapeutics (NASDAQ:AXSM) and maintained a $108 price target.
February 20, 2024 | 5:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald reaffirmed an Overweight rating on Axsome Therapeutics with a $108 price target.
The reiteration of an Overweight rating and a high price target by a reputable analyst like Charles Duncan from Cantor Fitzgerald could positively influence investor sentiment towards AXSM, potentially driving its stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100